|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing and Reimbursement News in the Second Quarter of 2008
Decision Resources, Inc., July 2008, Pages: 40
The United States stands in stark contrast to Europe and Japan in terms of the freedom that manufacturers have to set—and increase—the prices of branded drugs in the U S market However, pharmaceutical companies need to give careful thought to their pricing strategies in all markets Payers around the world are constantly adjusting their pharmaceutical cost-containment strategies
Get the Answers You Need to Shape Your Strategy:
- Leading pharmaceutical benefi t management companies (PBMs) in the United States are seeking new ways to contain prescription drug costs How do recent pricing trends for generics and branded drugs compare? What are PBMs doing to stimulate greater use of generics? What is the outlook for specialty pharmaceuticals?
- The French government has announced a major new cost-containment initiative. How will the government’s medical control strategy be used to save €500 million ($684 million) per year? Which categories of drugs are likely to be targets for price cuts? Which drug class could be subjected to reimbursement at the price level of generics?
- German health insurance funds recently cut reference prices in 59 reference pricing groups How many products now exceed their reference prices? What impact have the reference price cuts had on the availability of copayment-exempt drugs?
- The U K government has unveiled a new drug pricing and reimbursement system and a constitution for the National Health Service What effect will the new Pharmaceutical Price Regulation Scheme have on UK drug prices? How does the government plan to stimulate pharmaceutical innovation? How is the role of the National Institute for Health and Clinical Excellence (NICE) likely to change?
Scope:
- Issues affecting the pharmaceutical industry in the United States: recent spending trends; pricing; increasing use of generics; specialty pharmacy; Medicare reforms; new active surveillance system
- Issues affecting the pharmaceutical industry in Europe: expansion of European Commission antitrust investigation; French government’s new cost-containment strategy; impact of German reference pricing cuts; Italian prescribing trends; steady growth in the Spanish prescription drug market; price cuts agreed in negotiations for new U K drug pricing system
- Issues affecting the pharmaceutical industry in Japan: industry association’s proposed new pricing system; unprecedented focus on expanding the generics market
Key Developments in the Second Quarter of 2008:
- Medicare Reforms
- European Commission Expands Antitrust Investigation
- French Government Announces Plans for a Major New Cost-Containment Strategy
- Impact of Reference Price Cuts in Germany
- Price Cuts Agreed in Negotiations for New U K Drug Pricing System
- New NHS Constitution Promises Improved Market Access for Innovative Medicines in the United Kingdom
- Japan Pharmaceutical Manufacturers Association Proposes New Pricing System
- Unprecedented Focus on Expanding the Japanese Generics Market
Customers who bought this item also bought
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2006
Pharmaceutical Pricing and Reimbursement in Japan, 2008
Spotlight on Television 2.0 Leaders:?News Corp.
|
|
|
|
